We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Market for Proteomics Research Tools Facing Sharp Growth Trend

By LabMedica International staff writers
Posted on 05 Oct 2014
A report recently released to the biotech industry predicts sharp growth in research efforts in the field of proteomics with concurrent growth in sales of research supplies and equipment. More...


The report, “Proteomics Markets for Research and IVD Applications,” which was prepared by Kalorama Information (New York, NY, USA), indicated that the USD 5 billion market for proteomics instruments, reagents, and testing for research and diagnostic applications was likely to grow rapidly over the next several years, despite cost pressures generally in research.

Proteomics is the study of protein structure and function. At the cellular level, investigators attempt to determine which proteins are expressed, when and where they are expressed, what is their structure in both active and inactive states, what roles they play in the life of the cell, and how they interact with other proteins and molecules.

While many different types of technologies are used to study proteins, demands for the three main technologies: mass spectrometry, antibodies (or antibody capture), and knowledge bases are expected to grow significantly.

“It is enormously difficult to study proteins, but hard-fought discoveries made in the research enable biomarker discovery, drug discovery, new IVDs, and personalized solutions,” said Bruce Carlson, publisher of Kalorama Information. “There are many manufacturers willing to assist customers with technologies, creating a vibrant market. New platforms based on a wide range of proteomics technologies have already started to reach the in vitro diagnostics market. The major question today is not whether or not these novel platforms and biomarkers will emerge as a significant market opportunity in the IVD market, but when. How long will it take for companies to obtain the required regulatory approvals? How long will it take for the tests to penetrate these markets? The answers to this question will vary with individual platforms and assays, and will depend on factors such as the unmet need, how well the new platform and assays meet that need, costs, etc.”

Related Links:

Kalorama Information



New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Prefilled Tubes
Prefilled 5.0ml Tubes
New
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.